Research progress on immune checkpoint inhibitors combined with stereotactic ablative body radiotherapy for advanced non-small cell lung cancer
10.3760/cma.j.cn113030-20210924-00375
- VernacularTitle:晚期非小细胞肺癌免疫检查点抑制剂联合立体定向放疗研究进展
- Author:
Xiaofeng WANG
1
;
Hui BAI
;
Guoding HUANG
;
Feng LIU
;
Yuan YAO
;
Jun LIANG
Author Information
1. 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科，北京 100021
- Keywords:
Lung neoplasm/stereotactic radiotherapy;
Lung neoplasm/immunotherapy;
Immune checkpoint inhibitor
- From:
Chinese Journal of Radiation Oncology
2022;31(3):298-302
- CountryChina
- Language:Chinese
-
Abstract:
The effect of radiotherapy on anti-tumor immunity is bidirectional, immunotherapy, especially the combination of immune checkpoint inhibitors (ICIs) and radiotherapy, can produce synergistic effects on anti-tumor immunity. Compared with conventional radiotherapy, stereotactic ablative body radiotherapy (SABR) can achieve high-precision and high-dose irradiation on target lesions, and has stronger anti-tumor immune activation effect. At the same time, due to the steep dose gradient, SABR can better protect the surrounding normal tissues, which is an effective means for the rapid control of local lesions in advanced non-small cell lung cancer (NSCLC). ICIs are an important component of standard treatment for advanced NSCLC. There is growing evidence that SABR in combination with ICIs can benefit patients with advanced NSCLC. This article reviews the biological basis and clinical research progress on the combination of these two therapies, aiming to provide reference for the domestic counterparts to better use this new treatment model.
